<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">There are no antiviral agents that have proven efficacy in thetreatment of WNV infection. Ribavirin possesses in vitro activity but demonstrates poor clinical efficacy [
 <xref ref-type="bibr" rid="CR186">186</xref>, 
 <xref ref-type="bibr" rid="CR209">209</xref>]. IVIg with high titers of anti-WNV antibodies (e.g., from Israel, where infection is endemic) has demonstrated significant clinical benefits in animal models, although antibody titers are low in immune globulin derived from the US donors, which have proven ineffective in treating acute infection [
 <xref ref-type="bibr" rid="CR184">184</xref>, 
 <xref ref-type="bibr" rid="CR210">210</xref>, 
 <xref ref-type="bibr" rid="CR211">211</xref>]. A report of successful treatment of donor-transmitted WNV infection in a liver transplant recipient by reducing immunosuppression and administering plasma from seropositive blood donors has been published [
 <xref ref-type="bibr" rid="CR212">212</xref>]. Overall case fatality rates of infection with WNV are 4â€“20% [
 <xref ref-type="bibr" rid="CR189">189</xref>, 
 <xref ref-type="bibr" rid="CR192">192</xref>], with significantly higher rates in transplant recipients.
</p>
